Genotoxic, epigenetic, and transcriptomic effects of tamoxifen in mouse liver

Toxicology

Volumn 325, Issue , 2014, Pages 12-20

  de Conti, Aline ^a   Tryndyak, Volodymyr ^a   Churchwell, Mona I ^a   Melnyk, Stepan ^b   Latendresse, John R ^a   Muskhelishvili, Levan ^a   Beland, Frederick A ^a   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

DNA adducts; Epigenetics; Gene expression; Liver; Mouse; Tamoxifen

Indexed keywords

ALPHA(DEOXYGUANOSIN N 2 YL) N DESMETHYLTAMOXIFEN; ALPHA(DEOXYGUANOSIN N 2 YL)TAMOXIFEN; DNA; HISTONE; LIPOCALIN; LIPOCALIN 13; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG; AFIMOXIFENE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; COLLAGEN TYPE 1; CYTOCHROME P450 2D6; DNA METHYLTRANSFERASE 1; GLUCOSE; GLYCOGEN; LACTATE DEHYDROGENASE; NORTAMOXIFEN; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; ANTIESTROGEN; DNA ADDUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ADDUCT; DNA METHYLATION; DOWN REGULATION; DRUG EFFECT; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOTOXICITY; HISTONE MODIFICATION; HISTOPATHOLOGY; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CANCER; LIVER CARCINOGENESIS; LIVER TOXICITY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; TOXICOGENETICS; TRANSCRIPTOMICS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; FATTY ACID METABOLISM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTONE ACETYLATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER; LIVER INJURY; PROTEIN EXPRESSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; XENOBIOTIC METABOLISM; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; SPECIES DIFFERENCE; TIME;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA ADDUCTS; DNA METHYLATION; EPIGENESIS, GENETIC; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONES; LIVER; LIVER NEOPLASMS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK ASSESSMENT; SPECIES SPECIFICITY; TAMOXIFEN; TIME FACTORS;

EID: 84906488515     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.08.004     Document Type: Article

References (36)

1. Ables G.P. Update on Pparγ and nonalcoholic fatty liver disease. PPAR Res. 2012, 912351.
2. Bagnyukova T.V., Tryndyak V.P., Montgomery B., Churchwell M.I., Karpf A.R., James S.R., Muskhelishvili L., Beland F.A., Pogribny I.P. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29:638-646.
3. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 2012, 11:726-734.
4. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., White I.N.H. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002, 23:1897-1901.
5. Bruno S., Maisonneuve P., Castellana P., Rotmensz N., Rossi S., Maggioni M., Persico M., Colombo A., Monasterolo F., Casadei-Giunchi D., Desiderio F., Stroffolini T., Sacchini V., Decensi A., Veronesi U. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330:932.
6. Chen H., Li S., Liu J., Diwan B.A., Barret J.C., Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004, 25:1779-1786.
7. Cole L.K., Jacobs R.L., Vance D.E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2012, 52:1258-1265.
8. Davies R., Oreffo V.I.C., Martin E.A., Festing M.F.W., White I.N.H., Smith L.L., Styles J.A. Tamoxifen causes gene mutations in the livers of Lambda/lacI transgenic rats. Cancer Res. 1997, 57:1288-1293.
9. Derosa G., Maffioli P. Peroxisome proliferator-activated receptor-(PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr. Mol. Pharmacol. 2012, 5:272-281.
10. Fang H., Harris S.C., Su Z., Chen M., Qian F., Shi L., Perkins R., Tong W. ArrayTrack: an FDA and public genomic tool. Methods Mol. Biol. 2009, 563:379-398.
11. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86:527-537.
12. FitzGerald B.E., Shank R.C. Methylation status of DNA cytosine during the course of induction of liver cancer in hamsters by hydrazine sulfate. Carcinogenesis 1996, 17:2703-2709.
13. Gamboa da Costa G., Marques M.M., Beland F.A., Freeman J.P., Churchwell M.I., Doerge D.R. Quantification of tamoxifen-DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 2003, 16:357-366.
14. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 1993, 53:3919-3924.
15. Huidobro C., Fernandez A.F., Fraga M.F. The role of genetics in the establishment and maintence of the epigenome. Cell. Mol. Life Sci. 2013, 70:1543-1573.
16. Jones M.E., van Leeuwen F.E., Hoogendooorn W.E., Mourits M.J., Hollema H., van Boven H., Press M.F., Bernstein L., Swerdlow A.J. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012, 14:R91.
17. Kiyotani K., Mushiroda T., Nakamura Y., Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 2012, 27:122-131.
18. Lelliott C.J., Lopez M., Curtis R.K., Parker N., Laudes M., Yeo G., Jimenez-Linan M., Grosse J., Saha A.K., Wiggins D., Hauton D., Brand M.D., O'Rahilly S., Griffin J.L., Gibbons G.F., Vidal-Puig A. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005, 19:1108-1119.
19. Martin E.A., Carthew P., White I.N.H., Heydon R.T., Gaskell M., Mauthe R.J., Turteltaub K.W., Smith L.L. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis. 1997, 18:2209-2215.
20. Melnyk S., Pogribna M., Pogribny I.P., Yi P., James S.J. Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5'-phosphate concentrations. Clin. Chem. 2000, 46:265-272.
21. Miyashita T., Toyoda Y., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. J. Toxicol. Sci. 2012, 37:931-942.
22. Murata Y., Ogawa Y., Saibara T., Nishioka A., Fujiwara Y., Fukumoto M., Inomata T., Enzan H., Onishi S., Yoshida S. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol. Rep. 2000, 7:1299-1304.
23. Nan Y.-M., Han F., Kong L.-B., Zhao S.-X., Wang R.-Q., Wu W.-J., Yu J. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand. J. Gastroenterol. 2011, 46:358-369.
24. Oien K.A., Moffat D., Curry G.W., Dickson J., Habeshaw T., Mills P.R., MacSween R.N. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999, 353:36-37.
25. Paini A., Scholz G., Marin-Kuan M., Schilter B., O'Brien J., van Bladeren P.J., Rietjens I.M.C.M. Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays. Mutagenesis 2011, 26:605-618.
26. Pogribny I., Yi P., James S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem. Biophys. Res. Commun. 1999, 262:624-628.
27. Pogribny I.P., Bagnyukova T.V., Tryndyak V.P., Muskhelishvili L., Rodriguez-Juarez R., Kovalchuk O., Han T., Fuscoe J.C., Ross S.A., Beland F.A. Gene expression profiling reveals underlying molecular mechanisms of the early stages of tamoxifen-induced rat hepatocarcinogenesis. Toxicol. Appl. Pharmacol. 2007, 225:61-69.
28. Saphner T., Triest-Robertson S., Li H., Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009, 115:3189-3195.
29. Sheng L., Cho K.W., Zhou Y., Shen H., Rui L. Lipocalin 13 protein proitects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid β-oxidation. J. Biol. Chem. 2011, 286:38128-38135.
30. Tryndyak V.P., Muskhelishvili L., Kovalchuk O., Rodriguez-Juarez R., Montgomery B., Churchwell M.I., Ross S.A., Beland F.A., Pogribny I.P. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 2006, 27:1713-1720.
31. Tryndyak V.P., Kovalchuk O., Muskhelishvili L., Montgomery B., Rodriguez-Juarez R., Melnyk S., Ross S.A., Beland F.A., Pogribny I.P. Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarcinogenesis. Mol. Carcinog. 2007, 46:187-197.
32. Tryndyak V., de Conti A., Kobets T., Kutanzi K., Koturbash I., Han T., Fuscoe J.C., Latendresse J.R., Melnyk S., Shymonyak S., Collins L., Ross S.A., Rusyn I., Beland F.A., Pogribny I.P. Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism. FASEB J. 2012, 26:4592-4602.
33. Tucker M.J., Adams H.K., Patterson J.S. Tamoxifen. Safety Testing of New Drugs 1984, 125-161. Academic Press, New York. D.R. aurence, A.E.M. McLean, M. Weatherall (Eds.).
34. Umemoto A., Komaki K., Monden Y., Suwa M., Kanno Y., Kitagawa M., Suzuki M., Lin C.-X., Ueyama Y., Momen M.A., Ravindernath A., Shibutani S. Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol. 2001, 14:1006-1013.
35. Zhang F., Kong D., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to beside. Cell. Mol. Life Sci. 2013, 70:259-276.
36. Zheng H., Li S., Ma L., Cheng L., Deng C., Chen Z., Xie C., Xiang M., Jiang W., Chen L. A novel agonist of PPAR- γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytocine expression and preventing insulin resistance. Eur. J. Pharmacol. 2011, 659:244-251.